21,303 Shares in Repligen Co. (NASDAQ:RGEN) Acquired by Proficio Capital Partners LLC

Proficio Capital Partners LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 21,303 shares of the biotechnology company’s stock, valued at approximately $3,066,000.

Other hedge funds also recently made changes to their positions in the company. Resources Management Corp CT ADV purchased a new position in shares of Repligen in the 3rd quarter worth $37,000. Quarry LP raised its holdings in shares of Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 239 shares during the period. UMB Bank n.a. lifted its stake in shares of Repligen by 49.1% in the 4th quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares in the last quarter. Global Retirement Partners LLC lifted its stake in shares of Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 129 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Repligen by 15.2% during the 4th quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock worth $98,000 after purchasing an additional 90 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

Repligen stock opened at $157.67 on Thursday. Repligen Co. has a 52 week low of $113.50 and a 52 week high of $203.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.83 billion, a P/E ratio of -309.16, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The stock has a 50 day moving average of $156.74 and a 200-day moving average of $148.54.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target for the company. Royal Bank of Canada raised their price objective on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price for the company. Finally, Canaccord Genuity Group increased their target price on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $181.00.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.